Field evaluation of a novel oral reservoir-targeted vaccine against Borrelia burgdorferi utilizing an inactivated whole-cell bacterial antigen expression vehicle.

Autor: Stafford KC 3rd; Center for Vector Biology & Zoonotic Diseases, The Connecticut Agricultural Experiment Station, 123 Huntington Street, New Haven, CT, 06511, USA., Williams SC; Center for Vector Biology & Zoonotic Diseases, The Connecticut Agricultural Experiment Station, 123 Huntington Street, New Haven, CT, 06511, USA. scott.williams@ct.gov., van Oosterwijk JG; U.S. Biologic, Inc., Memphis, TN, USA., Linske MA; Center for Vector Biology & Zoonotic Diseases, The Connecticut Agricultural Experiment Station, 123 Huntington Street, New Haven, CT, 06511, USA., Zatechka S; U.S. Biologic, Inc., Memphis, TN, USA., Richer LM; U.S. Biologic, Inc., Memphis, TN, USA., Molaei G; Center for Vector Biology & Zoonotic Diseases, The Connecticut Agricultural Experiment Station, 123 Huntington Street, New Haven, CT, 06511, USA.; Department of Epidemiology of Microbial Diseases, School of Public Health, Yale University, New Haven, CT, USA., Przybyszewski C; U.S. Biologic, Inc., Memphis, TN, USA., Wikel SK; U.S. Biologic, Inc., Memphis, TN, USA.; Department of Medical Sciences, School of Medicine, Quinnipiac University, Hamden, CT, USA.
Jazyk: angličtina
Zdroj: Experimental & applied acarology [Exp Appl Acarol] 2020 Feb; Vol. 80 (2), pp. 257-268. Date of Electronic Publication: 2020 Jan 02.
DOI: 10.1007/s10493-019-00458-1
Abstrakt: Blacklegged ticks (Ixodes scapularis) are the principal vector for Borrelia burgdorferi, among other infectious agents, in the northeastern, mid-Atlantic, and upper midwestern USA. White-footed mice (Peromyscus leucopus) are the primary and most competent reservoir host of B. burgdorferi in the Northeast. Live reservoir-targeted vaccines (RTVs) to limit enzootic transmission of B. burgdorferi were previously developed and successfully evaluated in laboratory and controlled field trials. A novel, inactivated RTV was developed to minimize regulatory and market challenges facing previous RTVs based on live bacterial or viral vehicles. Thirty-two residential properties in Redding, Connecticut, participated in a field trial of an orally delivered, inactivated RTV efficacy study (2015-2016). During the two-year vaccination period, a significant decrease in the percentage of B. burgdorferi-infected I. scapularis larvae parasitizing P. leucopus was observed, as was a significant reduction in the percentage of infected P. leucopus on RTV-treated properties when compared to control properties. This novel inactivated RTV was effective in reducing numbers of B. burgdorferi-infected I. scapularis and B. burgdorferi-infected P. leucopus on properties where it was distributed.
Databáze: MEDLINE